Humacyte (HUMA) Stock
Biotech company developing living human blood vessel replacements. Here's the price, business snapshot, and what's worth knowing about Humacyte in October 2026.
Humacyte, Inc. (HUMA) is a clinical‑stage biotechnology company developing off‑the‑shelf, human acellular vessels (HAVs) intended to serve as living vascular grafts for people with vascular disease. The technology aims to provide a scalable, implantable conduit for indications such as dialysis access, peripheral arterial disease and surgical bypass. As a small‑cap, clinical‑stage company (market capitalisation around $320m), Humacyte’s value is driven by clinical trial outcomes, regulatory decisions and potential commercial partnerships rather than steady revenue. This profile means shares can be volatile and outcomes binary: positive clinical data or approvals could materially advance prospects, while setbacks may reduce valuation. Investors should consider clinical and regulatory risk, cash runway and dilution potential from future financing. This is educational information only and not financial advice — suitability depends on personal circumstances and investors may lose part or all of their investment.
Humacyte (HUMA) Stock Forecast
Analyst price target, next 12 months
$6.52
+1150.8% vs today's $0.52
Price range over the last 12 months
Close to its 12-month low
Analysts covering Humacyte have a consensus 12-month target of $6.52, above the current price of $0.52.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Humacyte's stock with a target price of $6.52, indicating strong growth potential.
Financial Health
Humacyte is generating modest revenue and cash flow, but faces challenges with its financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory milestones can move the share price significantly, though clinical outcomes are uncertain and binary in nature.
Regenerative Innovation
Off‑the‑shelf human acellular vessels address clear clinical needs and could attract partners, yet commercialisation and manufacturing scale‑up carry execution risk.
Potential Market Reach
Applications include dialysis access and vascular surgery across global markets, but adoption depends on clinical evidence, reimbursement and surgeon preference.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
